Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 14INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Neoplasms 3216Carcinoma, Non-Small-Cell Lung 2729Breast Neoplasms 2551Colorectal Neoplasms 1463Prostatic Neoplasms 1307Neoplasm Metastasis 1301Multiple Myeloma 1112Melanoma 1103Ovarian Neoplasms 1006Lung Neoplasms 945Recurrence 924Leukemia, Myeloid, Acute 879Pancreatic Neoplasms 833Lymphoma, Non-Hodgkin 767Lymphoma 713Stomach Neoplasms 692Carcinoma, Renal Cell 660Carcinoma, Hepatocellular 647Leukemia, Lymphocytic, Chronic, B-Cell 560Squamous Cell Carcinoma of Head and Neck 550Lymphoma, Follicular 515Head and Neck Neoplasms 490Glioblastoma 473Small Cell Lung Carcinoma 447Lymphoma, Large B-Cell, Diffuse 440Triple Negative Breast Neoplasms 436Advanced Solid Tumors 432Leukemia 426Uterine Cervical Neoplasms 420Urinary Bladder Neoplasms 405

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Sturge-Weber Syndrome × Clear all
NCT04947124 2025-01-20

A Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101

Qlaris Bio, Inc.

Phase 2 Completed
3 enrolled

Glaucoma, Hydrophthalmos, Ocular Hypertension, Sturge-Weber Syndrome

NCT05495269 2025-01-20

Safety and Tolerability Study of QLS-101 in Adolescents With Sturge-Weber Syndrome (SWS)-Related Glaucoma Due to Elevated Episcleral Venous Pressure (EVP)

Qlaris Bio, Inc.

Phase 2 Completed
2 enrolled

Glaucoma, Ocular Hypertension, Sturge-Weber Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡